Glukóza Braun (Glucose Monohydrate)

Glukóza Braun is a sterile intravenous solution containing glucose monohydrate as the active ingredient. It is supplied as a solution for injection, intended for parenteral administration. The product is manufactured in the European Union and is classified as an excipient/solvent used to provide carbohydrate energy and raise plasma glucose levels. It is commonly employed in clinical settings for hypoglycemia, parenteral nutrition, and fluid‑electrolyte replacement therapy.

Glukóza Braun is indicated for several clinical situations where rapid carbohydrate supplementation is required.

- Treatment of acute hypoglycemia in patients unable to take oral glucose. - Component of parenteral nutrition regimens to meet caloric needs. - Fluid and electrolyte replacement in perioperative or trauma care. - Support during diagnostic procedures that require fasting, such as PET scans. - Management of insulin‑induced hyperglycemia during intensive care.

Adverse reactions to Glukóza Braun are generally related to the intravenous administration of a carbohydrate solution.

Common: - Mild hyperglycemia. - Local irritation at the injection site. - Nausea or vomiting. - Transient electrolyte shifts (e.g., low potassium).

Serious: - Severe hyperglycemia with osmotic diuresis. - Allergic or anaphylactic reaction. - Volume overload leading to pulmonary edema. - Hyperosmolar hyperglycemic state.

When using Glukóza Braun, clinicians should consider several precautionary measures to ensure patient safety.

- Assess blood glucose levels before and during infusion. - Adjust infusion rate in patients with renal or cardiac impairment. - Monitor electrolyte concentrations, especially potassium and sodium. - Use caution in patients with known hypersensitivity to glucose solutions. - Avoid rapid large-volume administration in neonates and infants. - Ensure aseptic technique to prevent contamination.

Glukóza Braun may interact with other medications or clinical conditions, influencing its safety or efficacy.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring. - Concurrent use of hypertonic saline solutions that may exacerbate hyperosmolarity.

Use with caution: - Loop diuretics, which can affect fluid balance. - Beta‑blockers, which may mask hypoglycemia symptoms. - Corticosteroids, which can increase blood glucose levels. - Sodium‑containing medications that may contribute to volume overload.